<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neonatal shock: Management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neonatal shock: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neonatal shock: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Beau Batton, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard Martin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 12, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3985169913"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Shock is a dynamic and unstable pathophysiologic state characterized by inadequate tissue perfusion. Although the effects of inadequate perfusion are reversible initially, prolonged hypoperfusion and tissue hypoxia can disrupt critical biochemical processes, which, if not addressed, result in cell death, end-organ failure, and, possibly, death.</p><p>The classification and underlying mechanisms of neonatal shock are the same as those seen in pediatric and adult shock. However, the etiology, clinical manifestations, and initial management of neonatal shock differ somewhat from shock in other populations. (See  <a class="medical medical_review" href="/d/html/6396.html" rel="external">"Initial evaluation of shock in children"</a> and  <a class="medical medical_review" href="/d/html/1594.html" rel="external">"Definition, classification, etiology, and pathophysiology of shock in adults"</a>.)</p><p>The management of neonatal shock will be reviewed here. The etiology, clinical presentation, and evaluation of neonatal shock and the management of asymptomatic hypotension in extremely preterm neonates are discussed separately. (See  <a class="medical medical_review" href="/d/html/5039.html" rel="external">"Neonatal shock: Etiology, clinical manifestations, and evaluation"</a> and  <a class="medical medical_review" href="/d/html/109813.html" rel="external">"Assessment and management of low blood pressure in extremely preterm infants"</a>.)</p><p class="headingAnchor" id="H143789866"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>Shock, or circulatory failure, is defined as a physiologic state characterized by tissue hypoxia due to reduced oxygen delivery and/or increased oxygen consumption or inadequate oxygen utilization. It is manifested by physical findings of tissue hypoperfusion (eg, cold extremities, acrocyanosis, and poor capillary refill), tachycardia, and metabolic acidosis. Shock is often initially reversible, but must be recognized and treated immediately to prevent progression to irreversible organ dysfunction.</p><p>The causes of neonatal shock are classified into four pathophysiologic mechanisms  (<a class="graphic graphic_table graphicRef110373" href="/d/graphic/110373.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Hypovolemic</p><p class="bulletIndent1"><span class="glyph">●</span>Distributive</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiogenic</p><p class="bulletIndent1"><span class="glyph">●</span>Obstructive</p><p></p><p>However, neonatal shock may be the result of more than one of these processes (multifactorial shock). When the underlying mechanism is unclear or unknown, the term "undifferentiated shock" is used. (See  <a class="medical medical_review" href="/d/html/5039.html" rel="external">"Neonatal shock: Etiology, clinical manifestations, and evaluation", section on 'Etiologic classification'</a>.)</p><p>It is important to recognize that hypotension, which is commonly used to define shock states in adults, is generally a late finding of shock in neonates. Of note, blood pressure (BP) values vary considerably depending on gestational age (GA) and postnatal age  (<a class="graphic graphic_figure graphicRef110015" href="/d/graphic/110015.html" rel="external">figure 1</a>), particularly for extremely preterm (EPT) infants born &lt;28 weeks GA  (<a class="graphic graphic_figure graphicRef110007" href="/d/graphic/110007.html" rel="external">figure 2</a>). As such, defining hypotension in this population is challenging [<a href="#rid1">1</a>]. The definition of hypotension in EPT infants is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/109813.html" rel="external">"Assessment and management of low blood pressure in extremely preterm infants", section on 'Definitions'</a>.)</p><p class="headingAnchor" id="H2419209860"><span class="h1">INITIAL STABILIZATION</span><span class="headingEndMark"> — </span>Successful management of neonatal shock requires rapid intervention to restore perfusion regardless of the underlying etiology [<a href="#rid2">2</a>]. During the initial stabilization, evaluation to determine the etiology should occur concomitantly in order to best direct subsequent therapy  (<a class="graphic graphic_algorithm graphicRef128082" href="/d/graphic/128082.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H884452096"><span class="h2">Respiratory support</span><span class="headingEndMark"> — </span>The infant's airway and respiratory status should be assessed and stabilized, including administration of supplemental oxygen and/or mechanical ventilation. Neonates in shock often require endotracheal intubation and mechanical ventilation due to respiratory distress and/or apnea. (See  <a class="medical medical_review" href="/d/html/5032.html" rel="external">"Overview of mechanical ventilation in neonates"</a>.)</p><p class="headingAnchor" id="H4120392090"><span class="h2">Vascular access</span><span class="headingEndMark"> — </span>Vascular access should be established and blood samples obtained for initial testing. If feasible, a central line should be placed for frequent blood drawing, durable vascular access, and administration of vasoactive agents. Arterial access for invasive BP monitoring should also be considered, though this is not always necessary and placement of peripheral arterial lines can be challenging in neonates with poor perfusion. (See  <a class="medical medical_review" href="/d/html/6385.html" rel="external">"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies", section on 'Umbilical vein access'</a>.)</p><p class="headingAnchor" id="H1617872141"><span class="h2">Ongoing diagnostic evaluation</span><span class="headingEndMark"> — </span>A focused diagnostic evaluation is performed concomitantly with the resuscitation, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Brief review of the history</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Focused physical examination</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Basic laboratory tests (electrolytes, blood gas, complete blood count, lactate, blood culture, renal and liver function tests, and type and cross)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chest radiograph if respiratory symptoms are present</p><p></p><p>The diagnostic evaluation is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/5039.html" rel="external">"Neonatal shock: Etiology, clinical manifestations, and evaluation", section on 'Diagnostic evaluation'</a>.)</p><p class="headingAnchor" id="H2322153384"><span class="h2">Fluid resuscitation</span><span class="headingEndMark"> — </span>An initial intravenous (IV) fluid bolus of isotonic crystalloid (eg, normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> or Ringer's lactate) is appropriate for most neonates presenting with shock. Normal saline is the most commonly administered isotonic fluid in neonates [<a href="#rid3">3</a>].</p><p>The volume of fluid and rate of administration vary depending on the suspected underlying etiology and the gestational age:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypovolemic shock – Infants with hypovolemic shock due to acute blood loss generally require a large amount of fluid given fairly quickly. We generally start with 20 mL/kg of normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> over 15 minutes. Additional isotonic crystalloid and/or blood transfusion may be necessary, as discussed below. (See <a class="local">'Assess need for further fluid resuscitation'</a> below and <a class="local">'Acute blood loss'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Septic/distributive shock – For neonates with suspected septic or distributive shock, we suggest an initial fluid bolus of 10 to 20 mL/kg of isotonic crystalloid. In our center, we typically start with 20 mL/kg of normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> given over 15 to 30 minutes. Other centers may begin with smaller boluses (eg, 5 to 10 mL/kg) and/or administer the bolus more slowly. (See <a class="local">'Assess need for further fluid resuscitation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiogenic shock – Fluid bolus may not improve perfusion in patients with cardiogenic shock and in some cases may cause clinical deterioration. (See <a class="local">'Cardiac disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Undifferentiated shock – For neonates in whom the etiology of shock is uncertain, it is reasonable to administer an initial fluid bolus of 10 to 20 mL/kg and monitor carefully for signs of fluid responsiveness (ie, improved perfusion) or clinical deterioration. (See <a class="local">'Monitoring'</a> below and <a class="local">'Assess need for further fluid resuscitation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Caution in extremely preterm infants – Fluid boluses should be administered cautiously in extremely preterm infants (gestational age &lt;28 weeks) as rapid fluid administration exceeding 30 ml/kg is associated with an increased risk of intraventricular hemorrhage and death in this population [<a href="#rid4">4-6</a>]. (See  <a class="medical medical_review" href="/d/html/5051.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis"</a>.)</p><p></p><p>Further fluid resuscitation is generally dependent on the type of shock and is discussed below. (See <a class="local">'Assess need for further fluid resuscitation'</a> below.)</p><p class="headingAnchor" id="H1943261518"><span class="h2">Empiric antimicrobial therapy</span><span class="headingEndMark"> — </span>Prompt administration of empiric IV antibiotics is appropriate for all neonates presenting with shock after blood cultures are obtained because sepsis is the most common cause of neonatal shock. If there is clinical suspicion for herpes simplex virus (HSV) infection, the empiric antimicrobial regimen should include <a class="drug drug_pediatric" data-topicid="13247" href="/d/drug information/13247.html" rel="external">acyclovir</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic therapy</strong> – Pending culture results, the empiric antibiotic regimen should include agents active against organisms that most commonly cause neonatal sepsis (group B <em>streptococcus</em> and <em>Escherichia coli</em>). The combination of <a class="drug drug_pediatric" data-topicid="12683" href="/d/drug information/12683.html" rel="external">ampicillin</a> and <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a> provides appropriate empiric coverage for these organisms until culture results are available. Local antibiotic resistance patterns should also be considered. Empiric regimens used in term infants are summarized in the table  (<a class="graphic graphic_table graphicRef102574" href="/d/graphic/102574.html" rel="external">table 2</a>). Treatment of neonatal sepsis in term and preterm infants is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/5046.html" rel="external">"Management and outcome of sepsis in term and late preterm neonates", section on 'Initial empiric therapy'</a> and  <a class="medical medical_review" href="/d/html/89456.html" rel="external">"Treatment and prevention of bacterial sepsis in preterm infants &lt;34 weeks gestation", section on 'Empiric antibiotic therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiviral therapy</strong> – Disseminated HSV is another common cause of neonatal shock. When there is clinical suspicion for neonatal HSV infection, empiric <a class="drug drug_pediatric" data-topicid="13247" href="/d/drug information/13247.html" rel="external">acyclovir</a> therapy should be administered after appropriate viral testing is performed. The evaluation and treatment of neonatal HSV infection are discussed separately. (See  <a class="medical medical_review" href="/d/html/6037.html" rel="external">"Neonatal herpes simplex virus infection: Clinical features and diagnosis", section on 'Evaluation and diagnosis'</a> and  <a class="medical medical_review" href="/d/html/6040.html" rel="external">"Neonatal herpes simplex virus infection: Management and prevention", section on 'Initial antiviral therapy'</a>.)</p><p></p><p class="headingAnchor" id="H2109623323"><span class="h2">Other interventions</span><span class="headingEndMark"> — </span>Other physiologic disturbances may occur in neonates with shock, and if present, should be promptly corrected. These may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal glucose levels – Glucose levels should be monitored and both hyper- or hypoglycemia should be corrected. (See  <a class="medical medical_review" href="/d/html/101425.html" rel="external">"Management and outcome of neonatal hypoglycemia"</a> and  <a class="medical medical_review" href="/d/html/4981.html" rel="external">"Neonatal hyperglycemia", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypothermia. (See  <a class="medical medical_review" href="/d/html/5015.html" rel="external">"Neonatal resuscitation in the delivery room", section on 'Temperature control'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electrolyte disturbances. (See  <a class="medical medical_review" href="/d/html/5065.html" rel="external">"Fluid and electrolyte therapy in newborns"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia. (See  <a class="medical medical_review" href="/d/html/97752.html" rel="external">"Neonatal thrombocytopenia: Clinical manifestations, evaluation, and management", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coagulopathy. (See  <a class="medical medical_review" href="/d/html/5915.html" rel="external">"Disseminated intravascular coagulation in infants and children", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tension pneumothorax. (See  <a class="medical medical_review" href="/d/html/4995.html" rel="external">"Pulmonary air leak in the newborn", section on 'Thoracentesis'</a>.)</p><p></p><p class="headingAnchor" id="H2085029304"><span class="h1">ONGOING GOAL-DIRECTED THERAPY</span><span class="headingEndMark"> — </span>After the initial stabilization, ongoing management may include  (<a class="graphic graphic_algorithm graphicRef128082" href="/d/graphic/128082.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Ongoing assessment of fluid status and administration of additional fluid boluses as needed (see <a class="local">'Assess need for further fluid resuscitation'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administration of vasoactive medications to support cardiac output (CO) and/or improve vascular tone (see <a class="local">'Vasoactive agents'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administration of <a class="drug drug_pediatric" data-topicid="13361" href="/d/drug information/13361.html" rel="external">hydrocortisone</a> in neonates with refractory shock and/or suspected adrenal insufficiency (see <a class="local">'Hydrocortisone'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interventions targeting the suspected underlying cause (see <a class="local">'Interventions for suspected etiologies'</a> below)</p><p></p><p class="headingAnchor" id="H2659258640"><span class="h2">Goals</span><span class="headingEndMark"> — </span>The goal of the initial stabilization and ongoing management is to restore tissue perfusion. This is generally based on targeting improvements in physiologic parameters. However, some physiologic indicators may be less reliable in neonates due to the relative immaturity of the cardiovascular and nervous systems, technical challenges with invasive monitoring, and challenges of establishing intravenous (IV) access and obtaining blood samples in compromised neonates.</p><p>Nevertheless, we utilize the following physiological indicators to establish the goals of therapy and to monitor response to therapeutic interventions:</p><p class="bulletIndent1"><span class="glyph">●</span>Improvement in heart rate (HR):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decrease in HR for patients who are tachycardic (HR &gt;180 beats per minute)</p><p class="bulletIndent2"><span class="glyph">•</span>Increase in HR for patients who are bradycardic (HR &lt;90 beats per minute)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improvement in peripheral perfusion:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improving color and warmth of distal extremities</p><p class="bulletIndent2"><span class="glyph">•</span>Decreasing time for capillary refill</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increase in blood pressure (BP) for neonates with hypotension  (<a class="graphic graphic_figure graphicRef110007" href="/d/graphic/110007.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef110015" href="/d/graphic/110015.html" rel="external">figure 1</a>). The goal is to increase the BP to values observed before the onset of shock at a rate of 5 to 10 mmHg over several hours. A greater accelerated rate of rise in BP in preterm infants is associated with an increased risk of intraventricular hemorrhage (IVH). (See  <a class="medical medical_review" href="/d/html/5051.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resolution of metabolic acidosis – Evidence of resolving metabolic acidosis based on point-of-care testing as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increase in blood pH</p><p class="bulletIndent2"><span class="glyph">•</span>Increase in serum/plasma bicarbonate level</p><p class="bulletIndent2"><span class="glyph">•</span>Decrease in serum/plasma lactate</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improvement in neurologic status – Increased neurologic activity based on increased movement including facial expression (grimace), which is either spontaneous or in response to stimulation.</p><p></p><p>Although we use these specific parameters, it is important to recognize that they are evaluated together to provide an assessment of the infant's global condition. So for example, if we reach the BP goal but there are persistent signs of poor perfusion and elevated lactate levels, it is reasonable to assume that the chosen BP goal is not adequate and further intervention is warranted.</p><p>Similarly, escalation of intervention is not necessary, even when the BP goal has not been attained but the infant seems to be improving based on the other parameters (normalization of lactate levels and improved perfusion and neurologic examination).</p><p class="headingAnchor" id="H684714389"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>The management of neonatal shock requires close monitoring and observation of the following parameters to assess the hemodynamic status of the neonate:</p><p class="bulletIndent1"><span class="glyph">●</span>Continuous HR and pulse oximetry monitoring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Frequent BP monitoring (either continuously via an arterial line or non-invasive cuff measurements every 15 to 30 minutes).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical observation and assessment every one to two hours to evaluate changes in perfusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood gas monitoring every three to four hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urine output recorded at least every four hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electrolyte levels, complete blood counts, and coagulation studies measured several times per day.</p><p></p><p>The physiologic targets listed above (see <a class="local">'Goals'</a> above) should be assessed before and after each intervention to guide further management. In some cases, the infant's response to specific interventions may be helpful in identifying the underlying etiology (eg, clinical deterioration after fluid resuscitation may point to a primary cardiac etiology).</p><p>Since BP is not a reliable indicator of perfusion of critical organs (particularly the brain) in neonates, near-infrared spectroscopy (NIRS) has been proposed as a potentially more informative tool for monitoring perfusion [<a href="#rid7">7-10</a>]. NIRS measures blood flow and oxygenation to specific vital organs including the brain, gastrointestinal tract, and kidneys. Some studies have suggested that NIRS may be a useful tool for perioperative monitoring in neonates undergoing surgery for congenital heart disease (CHD) [<a href="#rid11">11,12</a>]. NIRS has also been used to monitor perfusion in preterm infants in the immediate postnatal period [<a href="#rid7">7,8</a>]. However, reliable data on its use for infants with neonatal shock are limited and insufficient. As a result, additional studies are needed before NIRS can be recommended for routine clinical use.</p><p class="headingAnchor" id="H3949795795"><span class="h2">Assess need for further fluid resuscitation</span><span class="headingEndMark"> — </span>Following the initial stabilization, ongoing assessment of the patient's volume status determines whether additional fluid boluses should be given. The response to initial fluid administration may vary depending on the underlying mechanism of shock (eg, hypovolemic, distributive, cardiogenic, or obstructive). (See  <a class="medical medical_review" href="/d/html/5039.html" rel="external">"Neonatal shock: Etiology, clinical manifestations, and evaluation", section on 'Etiologic classification'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with <strong>hypovolemic and distributive shock</strong> generally respond well to fluid administration unless there is concomitant cardiac dysfunction. Additional fluid boluses are often required, which are given as 10 to 20 mL/kg of isotonic crystalloid solutions (eg, normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> or Ringer's lactate) administered over 15 to 20 minutes. Normal saline is the most commonly administered isotonic fluid in neonates [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1">The patient's clinical response should be reassessed after each bolus (see <a class="local">'Monitoring'</a> above). Additional fluid should be given until the goals of therapy are reached or signs of fluid overload develop (eg, rales, worsening respiratory distress, increasing ventilator requirements, and hepatomegaly).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with <strong>distributive shock</strong> (eg, septic shock), 20 to 30 mL/kg of isotonic fluid is typically adequate for restoring intravascular blood volume. If the neonate has ongoing signs of shock despite adequate volume expansion, vasopressor therapy should be initiated (see <a class="local">'Vasoactive agents'</a> below). Excessive fluid administration (&gt;30 mL/kg) in preterm infants is associated with an increased risk of death and IVH [<a href="#rid4">4-6</a>]. (See  <a class="medical medical_review" href="/d/html/5051.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with <strong>hypovolemic shock</strong>, greater volumes of isotonic fluid and/or blood products may be needed before there is a clear improvement in hemodynamic status. (See <a class="local">'Acute blood loss'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with <strong>cardiogenic shock</strong>, fluid boluses may not improve perfusion. Volume expansion may in fact cause the neonate to deteriorate due to fluid overload (eg, rales, worsening respiratory distress, increasing ventilator requirements, and hepatomegaly) [<a href="#rid13">13</a>]. In these patients, additional fluid therapy should be avoided. When a cardiac etiology of shock is suspected, prompt echocardiography is essential to assess cardiac function and identify the underlying etiology. Prostaglandin E1 therapy should be initiated (even prior to echocardiography results) if there is strong clinical concern for ductal-dependent CHD  (<a class="graphic graphic_table graphicRef103087" href="/d/graphic/103087.html" rel="external">table 3</a>). (See <a class="local">'Cardiac disease'</a> below and  <a class="medical medical_review" href="/d/html/5785.html" rel="external">"Diagnosis and initial management of cyanotic heart disease in the newborn", section on 'Prostaglandin E1'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with <strong>obstructive shock</strong>, volume expansion helps to maintain CO by improving preload. However, therapy should focus on urgent correction of the underlying cause (eg, needle or chest tube thoracostomy for tension pneumothorax or pericardiocentesis for cardiac tamponade) as the neonate's hemodynamic status is unlikely to improve if the cause of the obstruction is not addressed. (See  <a class="medical medical_review" href="/d/html/4995.html" rel="external">"Pulmonary air leak in the newborn", section on 'Management'</a>.)</p><p></p><p class="headingAnchor" id="H2399621721"><span class="h2">Vasoactive agents</span><span class="headingEndMark"> — </span>Vasoactive agents are used to support neonates with distributive shock who have not improved with initial fluid resuscitation and those with cardiogenic shock who have ongoing ventricular dysfunction despite addressing reversible causes (eg, hypoxia, arrhythmia, hypothermia). Vasopressor therapy has little role in the management of patients with purely hemorrhagic or hypovolemic shock and may be harmful in this setting.</p><p>Commonly used vasoactive agents include <a class="drug drug_pediatric" data-topicid="13248" href="/d/drug information/13248.html" rel="external">dopamine</a>, <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a>, <a class="drug drug_pediatric" data-topicid="13243" href="/d/drug information/13243.html" rel="external">dobutamine</a>, and <a class="drug drug_pediatric" data-topicid="12613" href="/d/drug information/12613.html" rel="external">milrinone</a>. For neonates with distributive shock, we generally prefer dopamine based on greater clinical experience and familiarity with its use. There is less experience with epinephrine, and its pharmacologic properties are less well understood in neonates compared with older patients. The available clinical trial data suggest that dopamine and epinephrine have comparable efficacy, though epinephrine may be associated with more tachycardia and hyperglycemia [<a href="#rid14">14,15</a>]. The pharmacologic properties of these agents and their use in older children and adults are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/1619.html" rel="external">"Use of vasopressors and inotropes"</a> and  <a class="medical medical_review" href="/d/html/6397.html" rel="external">"Shock in children in resource-abundant settings: Initial management", section on 'Vasoactive agents'</a>.)</p><p>The pharmacokinetics of the various vasopressor agents are more variable in neonates compared with older patients and it is challenging to accurately predict the effects of these medications on CO, HR, and systemic vascular resistance (SVR).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dopamine</strong> – <a class="drug drug_pediatric" data-topicid="13248" href="/d/drug information/13248.html" rel="external">Dopamine</a> is commonly used as a first line agent for both distributive and cardiogenic shock because its effects are both inotropic (ie, it increases CO, which is the predominant effect at doses of 5 to 10 mcg/kg per min) and vasoconstrictive (ie, it increases SVR, which is the predominant effect at doses &gt;10 mcg/kg per min). Dopamine is infused beginning at a rate of 5 mcg/kg per min with titration up to a maximum of 15 mcg/kg per min based on the infant's clinical response. Careful titration is necessary because the response to the drug and its clearance can be unpredictable in neonates [<a href="#rid14">14,16-19</a>]. Some studies suggest dopamine can have a negative impact on CO due to an imbalance in vasopressor/inotrope activity [<a href="#rid16">16-18</a>]. Limited data suggest gestational and postnatal ages have little effect on dopamine pharmacokinetics [<a href="#rid20">20</a>]. In addition, plasma dopamine concentration cannot be predicted accurately from the dopamine infusion rate. Dopamine clearance is reduced in patients with renal or hepatic failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epinephrine</strong> – <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">Epinephrine</a> is a potent inotrope and at higher doses increases SVR. It is most commonly used as a second-line agent for distributive shock or as a first-line inotrope for severe cardiogenic shock. There are conflicting data on whether it is associated with more transient adverse effects compared with <a class="drug drug_pediatric" data-topicid="13248" href="/d/drug information/13248.html" rel="external">dopamine</a> [<a href="#rid14">14,15</a>]. Epinephrine is started at a rate of 0.05 mcg/kg/min and titrated up in increments of 0.01 mcg/kg/min based on response to a maximum of 1 mcg/kg per min based on the infant's clinical response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dobutamine</strong> – <a class="drug drug_pediatric" data-topicid="13243" href="/d/drug information/13243.html" rel="external">Dobutamine</a> is an inotrope that increases CO via improved myocardial contractility and increased HR. Dobutamine is an appropriate first-line agent for cardiogenic shock because of its inotropic properties. The impact of dobutamine on BP is highly variable in neonates, as it may increase BP, lower BP, or have little effect on BP [<a href="#rid19">19,21</a>]. In neonates, drug clearance is variable [<a href="#rid22">22</a>] and dobutamine appears to have a greater ability to increase CO compared with <a class="drug drug_pediatric" data-topicid="13248" href="/d/drug information/13248.html" rel="external">dopamine</a> [<a href="#rid23">23-25</a>]. Dobutamine infusion begins at a rate of 5 mcg/kg per min with titration up to a maximum of 20 mcg/kg per min based on the infant's clinical response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Milrinone</strong> – <a class="drug drug_pediatric" data-topicid="12613" href="/d/drug information/12613.html" rel="external">Milrinone</a> is a phosphodiesterase enzyme inhibitor that has inotropic and vasodilatory effects (ie, it increases CO and reduces SVR). Its use in neonatal shock is generally limited to neonates with confirmed cardiac disease and it should only be given in consultation with a pediatric cardiologist after obtaining an echocardiogram. There is limited dosing information available for neonates. The response to this agent is unpredictable in neonates and it frequently causes hypotension [<a href="#rid26">26,27</a>]. (See  <a class="medical medical_review" href="/d/html/14520.html" rel="external">"Heart failure in children: Management", section on 'Milrinone'</a>.)</p><p></p><p class="headingAnchor" id="H2999533393"><span class="h2">Hydrocortisone</span><span class="headingEndMark"> — </span>For neonates with distributive or cardiogenic shock that is refractory to fluid resuscitation and vasopressor therapy, we suggest administering <a class="drug drug_pediatric" data-topicid="13361" href="/d/drug information/13361.html" rel="external">hydrocortisone</a> [<a href="#rid28">28,29</a>].</p><p>For infants with known or suspected adrenal insufficiency based on clinical findings (eg, ambiguous genitalia), <a class="drug drug_pediatric" data-topicid="13361" href="/d/drug information/13361.html" rel="external">hydrocortisone</a> should be administered at an earlier stage in the management, if possible.</p><p><a class="drug drug_pediatric" data-topicid="13361" href="/d/drug information/13361.html" rel="external">Hydrocortisone</a> is given at an initial dose of 1 mg/kg IV. If there is a clinical response (rise in BP, weaning of vasopressors, and overall clinical improvement) within six to eight hours, it is generally continued at a dose of 0.5 to 1 mg/kg IV every eight hours. Hydrocortisone should be discontinued or weaned as the patient's condition improves, ideally within five days. (See <a class="local">'Suspected adrenal insufficiency'</a> below.)</p><p>This practice is supported by observational studies and a few small randomized trials that suggest <a class="drug drug_pediatric" data-topicid="13361" href="/d/drug information/13361.html" rel="external">hydrocortisone</a> may reduce the need for vasopressor therapy and shorten the duration of shock [<a href="#rid28">28,30</a>]. A reduction in mortality or long-term outcome has not been demonstrated.</p><p class="headingAnchor" id="H4271943961"><span class="h2">Interventions for suspected etiologies</span></p><p class="headingAnchor" id="H349992848"><span class="h3">Cardiac disease</span><span class="headingEndMark"> — </span>Cardiac disease may be suspected on the basis of any of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Physical findings (eg, murmur, gallop, weak or absent femoral pulses)</p><p class="bulletIndent1"><span class="glyph">●</span>Cyanosis that does not improve with administration of 100 percent oxygen</p><p class="bulletIndent1"><span class="glyph">●</span>Differential in pre- and postductal oxygen saturation</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical deterioration with fluid administration</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal rhythm on cardiac monitor</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal electrocardiogram</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal chest radiograph (eg, cardiomegaly, pulmonary edema)</p><p></p><p>If a cardiac etiology is suspected, additional interventions depend on the nature of the suspected cardiac problem (structural versus arrhythmia). Treatment decisions should generally be made in consultation with a pediatric cardiologist.</p><p>If there is strong clinical suspicion for<strong> ductal-dependent congenital heart disease</strong> (CHD)  (<a class="graphic graphic_table graphicRef103087" href="/d/graphic/103087.html" rel="external">table 3</a>), prompt administration of prostaglandin E1 (<a class="drug drug_pediatric" data-topicid="13353" href="/d/drug information/13353.html" rel="external">alprostadil</a>) is warranted. The typical starting dose is 0.01 mcg/kg per minute IV. Deterioration of the clinical status after starting prostaglandin E1 usually indicates the presence of rare congenital cardiac defects associated with pulmonary venous or left atrial obstruction. Echocardiography should be performed as soon as is possible to assess cardiac anatomy and function. The diagnosis and initial management of suspected ductal-dependent CHD is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5785.html" rel="external">"Diagnosis and initial management of cyanotic heart disease in the newborn"</a>.)</p><p>For neonates with <strong>arrhythmia</strong>:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bradycardia</strong> – Many preterm infants have transient apneic/bradycardic events that resolve spontaneously or with tactile stimulation or an increase in respiratory support. Neonates with persistent bradycardia should receive <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a> or <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> (if atrioventricular [AV] block is present) and cardiac compressions according to standard resuscitation algorithms  (<a class="graphic graphic_algorithm graphicRef129941" href="/d/graphic/129941.html" rel="external">algorithm 2</a>). Rarely, persistent bradycardia may require subsequent cardiac pacing. A pediatric cardiologist should be consulted promptly if the etiology of bradycardia is thought to be a primary cardiac rhythm disturbance (eg, congenital heart block). (See  <a class="medical medical_review" href="/d/html/5759.html" rel="external">"Bradycardia in children", section on 'Acute management of patients with poor perfusion'</a> and  <a class="medical medical_review" href="/d/html/912.html" rel="external">"Congenital third-degree (complete) atrioventricular block", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supraventricular tachycardia (SVT)</strong> – Patients with persistent SVT should be treated with initially with vagal maneuvers, followed by <a class="drug drug_pediatric" data-topicid="13258" href="/d/drug information/13258.html" rel="external">adenosine</a> (0.1 mg/kg/dose via rapid IV injection), or synchronized cardioversion (0.5 to 1 Joules/kg)  (<a class="graphic graphic_algorithm graphicRef129940" href="/d/graphic/129940.html" rel="external">algorithm 3</a>). (See  <a class="medical medical_review" href="/d/html/5782.html" rel="external">"Management of supraventricular tachycardia (SVT) in children", section on 'Unstable patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ventricular tachycardia</strong> – Patients with sustained ventricular tachycardia (VT) should undergo synchronized cardioversion  (<a class="graphic graphic_algorithm graphicRef129940" href="/d/graphic/129940.html" rel="external">algorithm 3</a>). Urgent consultation with pediatric cardiology is recommended for any neonate with sustained VT. (See  <a class="medical medical_review" href="/d/html/5758.html" rel="external">"Management and evaluation of wide QRS complex tachycardia in children", section on 'Unstable patient'</a>.)</p><p></p><p class="headingAnchor" id="H2739726795"><span class="h3">Septic shock</span><span class="headingEndMark"> — </span>The mainstays of therapy for septic shock consist of the interventions discussed above (ie, prompt administration of empiric antibiotics [and <a class="drug drug_pediatric" data-topicid="13247" href="/d/drug information/13247.html" rel="external">acyclovir</a> if there is concern for HSV], fluid resuscitation, vasopressor support if shock persists despite fluid administration, and <a class="drug drug_pediatric" data-topicid="13361" href="/d/drug information/13361.html" rel="external">hydrocortisone</a> for shock refractory to fluid resuscitation and vasopressors). (See <a class="local">'Empiric antimicrobial therapy'</a> above and <a class="local">'Fluid resuscitation'</a> above and <a class="local">'Vasoactive agents'</a> above and <a class="local">'Hydrocortisone'</a> above.)</p><p>For patients with persistent or worsening septic shock despite these interventions, additional measures may include the following, which generally should be undertaken in consultation with an infectious disease specialist:</p><p class="bulletIndent1"><span class="glyph">●</span>Broadening the antimicrobial coverage (eg, adding <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> if not already part of the empiric regimen, adding <a class="drug drug_pediatric" data-topicid="12583" href="/d/drug information/12583.html" rel="external">meropenem</a> if there is concern for a multidrug-resistant gram-negative organism, and adding coverage for fungal pathogens such as Candida). (See  <a class="medical medical_review" href="/d/html/5029.html" rel="external">"Treatment of Candida infection in neonates", section on 'Invasive infection'</a> and  <a class="medical medical_review" href="/d/html/6040.html" rel="external">"Neonatal herpes simplex virus infection: Management and prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Addressing any focal sources of infection, including removing a central line if it is suspected to be the source of infection, and evaluating for intra-abdominal pathology (eg, necrotizing enterocolitis, abscess, or malrotation with midgut volvulus), septic joint, osteomyelitis, or endocarditis. (See  <a class="medical medical_review" href="/d/html/89456.html" rel="external">"Treatment and prevention of bacterial sepsis in preterm infants &lt;34 weeks gestation", section on 'Source control'</a>.)</p><p></p><p>The management of neonatal sepsis and neonatal HSV are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/5046.html" rel="external">"Management and outcome of sepsis in term and late preterm neonates"</a> and  <a class="medical medical_review" href="/d/html/89456.html" rel="external">"Treatment and prevention of bacterial sepsis in preterm infants &lt;34 weeks gestation"</a> and  <a class="medical medical_review" href="/d/html/6040.html" rel="external">"Neonatal herpes simplex virus infection: Management and prevention"</a>.)</p><p class="headingAnchor" id="H1801194838"><span class="h3">Acute blood loss</span><span class="headingEndMark"> — </span>For neonates with significant blood loss, red blood cell (RBC) transfusion can be life-saving. In life-threatening circumstances, any available RBC product that is compatible with the infant's blood type can be administered. Additional details on RBC transfusion, including indications and selection of products, are provided in a separate topic review. (See  <a class="medical medical_review" href="/d/html/5041.html" rel="external">"Red blood cell (RBC) transfusions in the neonate"</a>.)</p><p>In addition to resuscitative measures, the source of bleeding should be identified if it is not readily apparent. Subgaleal hemorrhage usually can be diagnosed clinically but detection of intracranial hemorrhage requires cranial ultrasonography. (See  <a class="medical medical_review" href="/d/html/5031.html" rel="external">"Neonatal birth injuries", section on 'Subgaleal hemorrhage'</a> and  <a class="medical medical_review" href="/d/html/5051.html" rel="external">"Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Risk factors, clinical features, screening, and diagnosis", section on 'Cranial ultrasound'</a> and  <a class="medical medical_review" href="/d/html/5031.html" rel="external">"Neonatal birth injuries"</a>.)</p><p>Ultrasonography can also detect bleeding into the abdomen or kidney. A positive test for fetal cells in a sample of maternal blood can be indicative of fetomaternal hemorrhage as a cause for hypovolemic shock [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/6806.html" rel="external">"Spontaneous massive fetomaternal hemorrhage", section on 'Kleihauer-Betke assay'</a>.)</p><p class="headingAnchor" id="H1711689851"><span class="h3">Suspected adrenal insufficiency</span><span class="headingEndMark"> — </span>Adrenal insufficiency due to impaired synthesis or release of adrenocortical hormones may cause or contribute to shock.</p><p class="bulletIndent1"><span class="glyph">●</span>Primary adrenal insufficiency (eg, congenital adrenal hyperplasia [CAH]) may be suspected based on the physical finding of ambiguous genitalia and laboratory findings of hyperkalemia, hyponatremia, and hypoglycemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Secondary or relative adrenal insufficiency may be suspected in patients with refractory shock (ie, failure to respond to fluid resuscitation and vasoactive agents).</p><p></p><p>In both settings, intravenous <a class="drug drug_pediatric" data-topicid="13361" href="/d/drug information/13361.html" rel="external">hydrocortisone</a> is administered. (See <a class="local">'Hydrocortisone'</a> above.)</p><p>CAH is discussed in further detail separately. (See  <a class="medical medical_review" href="/d/html/145.html" rel="external">"Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"</a> and  <a class="medical medical_review" href="/d/html/5800.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"</a>.)</p><p class="headingAnchor" id="H995225928"><span class="h3">Undifferentiated shock</span><span class="headingEndMark"> — </span>In some cases, the underlying etiology remains uncertain. Continued general support including fluid therapy, vasopressor support, and ongoing antimicrobial therapy is provided while further diagnostic evaluation is pursued. In addition, we suggest <a class="drug drug_pediatric" data-topicid="13361" href="/d/drug information/13361.html" rel="external">hydrocortisone</a> for infants who remain refractory to supportive measures. (See <a class="local">'Assess need for further fluid resuscitation'</a> above and <a class="local">'Vasoactive agents'</a> above and <a class="local">'Empiric antimicrobial therapy'</a> above and <a class="local">'Hydrocortisone'</a> above.)</p><p>The patient's status should be reevaluated frequently with clinical assessments and repeat laboratory testing. If physiologic or laboratory abnormalities are identified (eg, fever, hypothermia, electrolyte derangements, hypoglycemia, coagulopathy), they should be addressed promptly since these findings can contribute to the ongoing shock state. (See <a class="local">'Monitoring'</a> above and <a class="local">'Other interventions'</a> above.)</p><p>Additional evaluation is discussed separately and may include (see  <a class="medical medical_review" href="/d/html/5039.html" rel="external">"Neonatal shock: Etiology, clinical manifestations, and evaluation", section on 'Additional selective testing'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Echocardiography to assess cardiac anatomy and function</p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal imaging to assess for necrotizing enterocolitis</p><p class="bulletIndent1"><span class="glyph">●</span>Cranial ultrasound to assess for intracranial hemorrhage</p><p class="bulletIndent1"><span class="glyph">●</span>Lumbar puncture (if clinical status permits) to assess for meningitis</p><p></p><p class="headingAnchor" id="H2305266552"><span class="h1">SEVERE REFRACTORY SHOCK</span><span class="headingEndMark"> — </span>In some centers, extracorporeal membrane oxygenation (ECMO) may be offered to patients who have ongoing severe shock despite maximal medical management, including aggressive fluid management and inotropic support. Although there is some variability among institutions with ECMO capability, general requirements include the following: </p><p class="bulletIndent1"><span class="glyph">●</span>Birth weight &gt;1800 g.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postmenstrual age &gt;34 weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reversible lung disease without an anticipated need for prolonged mechanical ventilation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No evidence of cyanotic congenital heart disease (CHD), although ECMO may be used in the perioperative period to support neonates with CHD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No other conditions that would be considered contraindications to ECMO, including multiple organ system failure; contraindications to full anticoagulation (eg, coagulopathy, grade 2 or greater intracranial hemorrhage); massive cerebral edema; irreversible pulmonary or cardiac disease; or multiple congenital anomalies.</p><p></p><p class="headingAnchor" id="H3911409345"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial stabilization</strong> – Successful management of neonatal shock requires rapid intervention to restore perfusion regardless of the underlying etiology. During the initial stabilization, evaluation to determine the etiology should occur concomitantly in order to best direct subsequent therapy  (<a class="graphic graphic_algorithm graphicRef128082" href="/d/graphic/128082.html" rel="external">algorithm 1</a>). Initial stabilization includes (see <a class="local">'Initial stabilization'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Providing appropriate respiratory support (see  <a class="medical medical_review" href="/d/html/5032.html" rel="external">"Overview of mechanical ventilation in neonates"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Obtaining vascular access (see  <a class="medical medical_review" href="/d/html/6385.html" rel="external">"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies", section on 'Umbilical vein access'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ongoing diagnostic evaluation (see  <a class="medical medical_review" href="/d/html/5039.html" rel="external">"Neonatal shock: Etiology, clinical manifestations, and evaluation", section on 'Diagnostic evaluation'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administering a fluid bolus (20 mL/kg isotonic crystalloid over 10 to 15 minutes) (see <a class="local">'Fluid resuscitation'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administering empiric antimicrobials (see <a class="local">'Empiric antimicrobial therapy'</a> above and  <a class="medical medical_review" href="/d/html/5046.html" rel="external">"Management and outcome of sepsis in term and late preterm neonates", section on 'Initial empiric therapy'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Addressing any correctable abnormalities noted on the initial evaluation (see <a class="local">'Other interventions'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring response to therapy</strong> – The neonate should be assessed before and after each intervention to guide further management. In some cases, the infant's response to an intervention may help identify the underlying etiology (eg, clinical deterioration after fluid resuscitation may point to a primary cardiac etiology). The following physiologic indicators are used to monitor the response to therapy (see <a class="local">'Monitoring'</a> above and <a class="local">'Goals'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improvement in heart rate</p><p class="bulletIndent2"><span class="glyph">•</span>Improvement in the quality of central and peripheral pulses</p><p class="bulletIndent2"><span class="glyph">•</span>Improvement of skin perfusion</p><p class="bulletIndent2"><span class="glyph">•</span>Improved acid-base balance (resolving metabolic acidosis, decreasing lactate level)</p><p class="bulletIndent2"><span class="glyph">•</span>Improvement in neurologic status (grimace, spontaneous movement, response to stimulation, presence of normal newborn reflexes)</p><p class="bulletIndent2"><span class="glyph">•</span>Rise in blood pressure if hypotensive</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ongoing management</strong> – After the initial stabilization, ongoing management includes  (<a class="graphic graphic_algorithm graphicRef128082" href="/d/graphic/128082.html" rel="external">algorithm 1</a>) (see <a class="local">'Ongoing goal-directed therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fluid therapy – The fluid status should be reassessed frequently and additional fluid boluses given as needed until goals of therapy are reached or signs of fluid overload develop. (See <a class="local">'Assess need for further fluid resuscitation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vasoactive medications – Vasoactive medications are used to support cardiac output and/or improve vascular tone in patients with persistent shock despite adequate fluid resuscitation. For most neonates with distributive shock, we suggest <a class="drug drug_pediatric" data-topicid="13248" href="/d/drug information/13248.html" rel="external">dopamine</a> as the initial vasopressor agent rather than <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). This is based largely on greater experience with dopamine in this setting. Both agents appear to have comparable efficacy. For patients with cardiogenic shock, <a class="drug drug_pediatric" data-topicid="13243" href="/d/drug information/13243.html" rel="external">dobutamine</a>, dopamine, and epinephrine are all reasonable choices for inotropic support. <a class="drug drug_pediatric" data-topicid="12613" href="/d/drug information/12613.html" rel="external">Milrinone</a> is also a reasonable choice, but it frequently causes hypotension, and therefore it generally should be used in consultation with a cardiologist. (See <a class="local">'Vasoactive agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13361" href="/d/drug information/13361.html" rel="external">Hydrocortisone</a> – For neonates with persistent distributive or cardiogenic shock that is refractory to fluid resuscitation and vasopressor therapy, we suggest administering hydrocortisone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Hydrocortisone should be administered at an earlier stage in the management if the infant has known or suspected primary adrenal insufficiency based on clinical findings (eg, ambiguous genitalia). (See <a class="local">'Hydrocortisone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional interventions</strong> – Additional interventions may be warranted depending on the underlying etiology (see <a class="local">'Interventions for suspected etiologies'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Suspected structural cardiac disease – If there is strong clinical suspicion for ductal-dependent congenital heart disease (CHD)  (<a class="graphic graphic_table graphicRef103087" href="/d/graphic/103087.html" rel="external">table 3</a>), prostaglandin E1 (<a class="drug drug_pediatric" data-topicid="13353" href="/d/drug information/13353.html" rel="external">alprostadil</a>) should be started promptly. Echocardiography should be performed as soon as is possible to assess cardiac anatomy and function. (See  <a class="medical medical_review" href="/d/html/5785.html" rel="external">"Diagnosis and initial management of cyanotic heart disease in the newborn", section on 'Prostaglandin E1'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Arrhythmia – Supraventricular or ventricular tachyarrhythmias associated with acute hemodynamic instability should be converted without delay  (<a class="graphic graphic_algorithm graphicRef129940" href="/d/graphic/129940.html" rel="external">algorithm 3</a>). Bradycardia should be treated with <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a> or <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> according to standard resuscitation algorithms  (<a class="graphic graphic_algorithm graphicRef129941" href="/d/graphic/129941.html" rel="external">algorithm 2</a>). A pediatric cardiologist should be consulted promptly if the etiology of bradycardia is thought to be a primary cardiac rhythm disturbance (eg, congenital heart block). (See  <a class="medical medical_review" href="/d/html/5782.html" rel="external">"Management of supraventricular tachycardia (SVT) in children"</a> and  <a class="medical medical_review" href="/d/html/5758.html" rel="external">"Management and evaluation of wide QRS complex tachycardia in children"</a> and  <a class="medical medical_review" href="/d/html/912.html" rel="external">"Congenital third-degree (complete) atrioventricular block"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Refractory septic shock ‒ For patients with persistent or worsening septic shock despite administration of empiric antimicrobials, fluid resuscitation, vasopressor support, and <a class="drug drug_pediatric" data-topicid="13361" href="/d/drug information/13361.html" rel="external">hydrocortisone</a>, additional measures may include broadening antimicrobial coverage and addressing any focal source of infection. (See <a class="local">'Septic shock'</a> above and  <a class="medical medical_review" href="/d/html/5046.html" rel="external">"Management and outcome of sepsis in term and late preterm neonates"</a> and  <a class="medical medical_review" href="/d/html/89456.html" rel="external">"Treatment and prevention of bacterial sepsis in preterm infants &lt;34 weeks gestation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute blood loss – For neonates with significant blood loss, red blood cell (RBC) transfusion can be life-saving. In life-threatening circumstances, any available RBC product that is compatible with the infant's blood type can be administered. (See  <a class="medical medical_review" href="/d/html/5041.html" rel="external">"Red blood cell (RBC) transfusions in the neonate"</a>.)</p><p></p><p class="headingAnchor" id="H2967610820"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Lisa Adcock, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Goldsmith JP, Keels E. Recognition and Management of Cardiovascular Insufficiency in the Very Low Birth Weight Newborn. Pediatrics 2022; 149.</a></li><li><a class="nounderline abstract_t">Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock. Crit Care Med 2017; 45:1061.</a></li><li><a class="nounderline abstract_t">Uhing MR. The albumin controversy. Clin Perinatol 2004; 31:475.</a></li><li><a class="nounderline abstract_t">Tyler W, Ewer AK. The use of volume expansion in preterm infants. Paediatr Perinat Epidemiol 2004; 18:135.</a></li><li><a class="nounderline abstract_t">Dempsey EM. What Should We Do about Low Blood Pressure in Preterm Infants. Neonatology 2017; 111:402.</a></li><li><a class="nounderline abstract_t">Lee HJ, Lee BS, Do HJ, et al. Early sodium and fluid intake and severe intraventricular hemorrhage in extremely low birth weight infants. J Korean Med Sci 2015; 30:283.</a></li><li><a class="nounderline abstract_t">Hyttel-Sorensen S, Pellicer A, Alderliesten T, et al. Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial. BMJ 2015; 350:g7635.</a></li><li><a class="nounderline abstract_t">Kato R, Hosono S, Takahashi S. Reference Value of Brain Tissue Oxygen Saturation in Newborns Immediately After Birth. Adv Exp Med Biol 2020; 1232:19.</a></li><li><a class="nounderline abstract_t">Seager E, Longley C, Aladangady N, Banerjee J. Measurement of gut oxygenation in the neonatal population using near-infrared spectroscopy: a clinical tool? Arch Dis Child Fetal Neonatal Ed 2020; 105:76.</a></li><li><a class="nounderline abstract_t">de Roever I, Bale G, Mitra S, et al. Investigation of the Pattern of the Hemodynamic Response as Measured by Functional Near-Infrared Spectroscopy (fNIRS) Studies in Newborns, Less Than a Month Old: A Systematic Review. Front Hum Neurosci 2018; 12:371.</a></li><li><a class="nounderline abstract_t">Hirsch JC, Charpie JR, Ohye RG, Gurney JG. Near-infrared spectroscopy: what we know and what we need to know--a systematic review of the congenital heart disease literature. J Thorac Cardiovasc Surg 2009; 137:154.</a></li><li><a class="nounderline abstract_t">Spaeder MC, Klugman D, Skurow-Todd K, et al. Perioperative Near-Infrared Spectroscopy Monitoring in Neonates With Congenital Heart Disease: Relationship of Cerebral Tissue Oxygenation Index Variability With Neurodevelopmental Outcome. Pediatr Crit Care Med 2017; 18:213.</a></li><li><a class="nounderline abstract_t">Yager P, Noviski N. Shock. Pediatr Rev 2010; 31:311.</a></li><li><a class="nounderline abstract_t">Baske K, Saini SS, Dutta S, Sundaram V. Epinephrine versus dopamine in neonatal septic shock: a double-blind randomized controlled trial. Eur J Pediatr 2018; 177:1335.</a></li><li><a class="nounderline abstract_t">Valverde E, Pellicer A, Madero R, et al. Dopamine versus epinephrine for cardiovascular support in low birth weight infants: analysis of systemic effects and neonatal clinical outcomes. Pediatrics 2006; 117:e1213.</a></li><li><a class="nounderline abstract_t">Rozé JC, Tohier C, Maingueneau C, et al. Response to dobutamine and dopamine in the hypotensive very preterm infant. Arch Dis Child 1993; 69:59.</a></li><li><a class="nounderline abstract_t">Osborn D, Evans N, Kluckow M. Randomized trial of dobutamine versus dopamine in preterm infants with low systemic blood flow. J Pediatr 2002; 140:183.</a></li><li><a class="nounderline abstract_t">Phillipos EZ, Barrington KJ, Robertson MA. Dopamine versus epinephrine for inotropic support in the neonate: A randomised blinded trial. Pediatr Res 1996; 39:A238.</a></li><li><a class="nounderline abstract_t">Dempsey E, Rabe H. The Use of Cardiotonic Drugs in Neonates. Clin Perinatol 2019; 46:273.</a></li><li><a class="nounderline abstract_t">Zaritsky A, Lotze A, Stull R, Goldstein DS. Steady-state dopamine clearance in critically ill infants and children. Crit Care Med 1988; 16:217.</a></li><li><a class="nounderline abstract_t">Mahoney L, Shah G, Crook D, et al. A Literature Review of the Pharmacokinetics and Pharmacodynamics of Dobutamine in Neonates. Pediatr Cardiol 2016; 37:14.</a></li><li><a class="nounderline abstract_t">Pellicer A, Fernández R, Jullien V, et al. Pharmacokinetic study (phase I-II) of a new dobutamine formulation in preterm infants immediately after birth. Pediatr Res 2021; 89:981.</a></li><li><a class="nounderline abstract_t">Bravo MC, López-Ortego P, Sánchez L, et al. Randomized, Placebo-Controlled Trial of Dobutamine for Low Superior Vena Cava Flow in Infants. J Pediatr 2015; 167:572.</a></li><li><a class="nounderline abstract_t">Mielgo VE, Valls-I-Soler A, Lopez-de-Heredia JM, et al. Hemodynamic and metabolic effects of a new pediatric dobutamine formulation in hypoxic newborn pigs. Pediatr Res 2017; 81:511.</a></li><li><a class="nounderline abstract_t">Klarr JM, Faix RG, Pryce CJ, Bhatt-Mehta V. Randomized, blind trial of dopamine versus dobutamine for treatment of hypotension in preterm infants with respiratory distress syndrome. J Pediatr 1994; 125:117.</a></li><li><a class="nounderline abstract_t">Hallik M, Tasa T, Starkopf J, Metsvaht T. Dosing of Milrinone in Preterm Neonates to Prevent Postligation Cardiac Syndrome: Simulation Study Suggests Need for Bolus Infusion. Neonatology 2017; 111:8.</a></li><li><a class="nounderline abstract_t">Paradisis M, Evans N, Kluckow M, Osborn D. Randomized trial of milrinone versus placebo for prevention of low systemic blood flow in very preterm infants. J Pediatr 2009; 154:189.</a></li><li><a class="nounderline abstract_t">Noori S, Friedlich P, Wong P, et al. Hemodynamic changes after low-dosage hydrocortisone administration in vasopressor-treated preterm and term neonates. Pediatrics 2006; 118:1456.</a></li><li><a class="nounderline abstract_t">Watterberg KL. Hydrocortisone Dosing for Hypotension in Newborn Infants: Less Is More. J Pediatr 2016; 174:23.</a></li><li><a class="nounderline abstract_t">Ibrahim H, Sinha IP, Subhedar NV. Corticosteroids for treating hypotension in preterm infants. Cochrane Database Syst Rev 2011; :CD003662.</a></li><li><a class="nounderline abstract_t">Markham LA, Charsha DS, Perelmuter B. Case report of massive fetomaternal hemorrhage and a guideline for acute neonatal management. Adv Neonatal Care 2006; 6:197.</a></li></ol></div><div id="topicVersionRevision">Topic 126605 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35224636" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Recognition and Management of Cardiovascular Insufficiency in the Very Low Birth Weight Newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28509730" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15325533" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The albumin controversy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14996253" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The use of volume expansion in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28538235" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : What Should We Do about Low Blood Pressure in Preterm Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25729251" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Early sodium and fluid intake and severe intraventricular hemorrhage in extremely low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25569128" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31893389" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Reference Value of Brain Tissue Oxygen Saturation in Newborns Immediately After Birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31154420" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Measurement of gut oxygenation in the neonatal population using near-infrared spectroscopy: a clinical tool?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30333736" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Investigation of the Pattern of the Hemodynamic Response as Measured by Functional Near-Infrared Spectroscopy (fNIRS) Studies in Newborns, Less Than a Month Old: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19154918" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Near-infrared spectroscopy: what we know and what we need to know--a systematic review of the congenital heart disease literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28067688" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Perioperative Near-Infrared Spectroscopy Monitoring in Neonates With Congenital Heart Disease: Relationship of Cerebral Tissue Oxygenation Index Variability With Neurodevelopmental Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20679096" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29936590" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Epinephrine versus dopamine in neonatal septic shock: a double-blind randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16717120" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Dopamine versus epinephrine for cardiovascular support in low birth weight infants: analysis of systemic effects and neonatal clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8346957" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Response to dobutamine and dopamine in the hypotensive very preterm infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11865269" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Randomized trial of dobutamine versus dopamine in preterm infants with low systemic blood flow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Dopamine versus epinephrine for inotropic support in the neonate: A randomised blinded trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31010560" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The Use of Cardiotonic Drugs in Neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3342635" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Steady-state dopamine clearance in critically ill infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26346024" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A Literature Review of the Pharmacokinetics and Pharmacodynamics of Dobutamine in Neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32610341" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pharmacokinetic study (phase I-II) of a new dobutamine formulation in preterm infants immediately after birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26116470" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Randomized, Placebo-Controlled Trial of Dobutamine for Low Superior Vena Cava Flow in Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27886191" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hemodynamic and metabolic effects of a new pediatric dobutamine formulation in hypoxic newborn pigs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8021760" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Randomized, blind trial of dopamine versus dobutamine for treatment of hypotension in preterm infants with respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27490706" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Dosing of Milrinone in Preterm Neonates to Prevent Postligation Cardiac Syndrome: Simulation Study Suggests Need for Bolus Infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18822428" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Randomized trial of milrinone versus placebo for prevention of low systemic blood flow in very preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17015536" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hemodynamic changes after low-dosage hydrocortisone administration in vasopressor-treated preterm and term neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27156187" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hydrocortisone Dosing for Hypotension in Newborn Infants: Less Is More.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22161379" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Corticosteroids for treating hypotension in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16890132" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Case report of massive fetomaternal hemorrhage and a guideline for acute neonatal management.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
